Gain Therapeutics, Inc. cotiza a 1.41 USD y tiene una capitalización bursátil de $62M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies propri…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.13 | $-0.11 | $-0.15 | $-0.19 |
| Estimado | $-0.14 | $-0.14 | $-0.15 | $-0.17 |
| Sorpresa | +7.1% | +21.4% | +0.0% | -11.8% |
| Métrica | GANX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -108.6% | -40.4% | -68.2% |
| ROA | -88.3% | -32.0% | -56.3% |
| Current Ratio | 6.63 | 2.84 | +3.79 |
| Debt / Equity | 0.02 | 0.28 | -0.26 |